| INTRODUC TI ON
In mammalian cells, the major processes of ATP production from glucose are mitochondrial electron transport and oxidative phosphorylation, both of which depend on oxygen. The tricarboxylic acid (TCA) cycle in mitochondria is also an oxygen-dependent system as some co-enzymes, such as NAD, are provided from the mitochondrial electron transport system. Glucose metabolism is generally activated in tumor cells. Notably, many tumor cells are known to utilize glycolysis, an oxygen-independent process, even in the normoxia condition. 1 This phenomenon, known as the Warburg effect, was first identified by Otto Warburg in the 1920s. 1 The impact of hypoxia on cancer pathogenesis has also been well documented since the report by Thomlinson and Gray in the 1950s. 2 They identified the presence of hypoxic cells surrounding the necrotic tumor center in histological sections of carcinomas. 2 Several decades after this first description of hypoxic cells, Wang and Semenza discovered hypoxia-inducible factor-1α (HIF1A), a critical transcription factor for hypoxia adaptation. 3 Although HIF1A
was initially identified as a key factor for response to hypoxia and many phenomena in hypoxic response result from HIF1A signaling activation, [4] [5] [6] recent accumulating evidence has revealed a variety of hypoxia-independent mechanisms for HIF1A signaling activation. 7, 8 These mechanisms could induce a pseudohypoxic condition even when a sufficient level of oxygen is present. The coined term
Since the first identification of hypoxic cells in sections of carcinomas in the 1950s, hypoxia has been known as a central hallmark of cancer cells and their microenvironment. Indeed, hypoxia benefits cancer cells in their growth, survival, and metastasis.
The historical discovery of hypoxia-inducible factor-1α (HIF1A) in the early 1990s had a great influence on the field as many phenomena in hypoxia could be explained by HIF1A. However, not all regions or types of tumors are necessarily hypoxic. Thus, it is difficult to explain whole cancer pathobiology by hypoxia, especially in the early stage of cancer. Upregulation of glucose metabolism in cancer cells has been well known. Oxygen-independent glycolysis is activated in cancer cells even in the normoxia condition, which is known as the Warburg effect. Accumulating evidence and recent advances in cancer metabolism research suggest that hypoxia-independent mechanisms for HIF signaling activation is a hallmark for cancer. There are various mechanisms that generate pseudohypoxic conditions, even in normoxia. Given the importance of HIF1A for cancer pathobiology, the pseudohypoxia concept could shed light on the longstanding mystery of the Warburg effect and accelerate better understanding of the diverse phenomena seen in a variety of cancers.
K E Y W O R D S
HIF1A, hypoxia, oncometabolite, pseudohypoxia, Warburg effect "pseudohypoxia" was originally used for the phenomena of hypoxialike metabolic changes in diabetes. 9 As many phenomena in hypoxia could be explained by HIF1A, hypoxia-independent activation of HIF1A signaling could mimic many hypoxia-mediated phenomena, even in the normoxia condition. Thus, these mechanisms underlying oxygen-independent activation of HIF1A signaling are now termed pseudohypoxia. [10] [11] [12] [13] From this perspective, we describe an overview of pseudohypoxia in cancer and recent findings.
| OX YG EN -DEPENDENTAC TIVATI ONOF HIF1 A
Hypoxia-inducible factor-1α was originally identified as a critical factor for cellular adaptation to hypoxic conditions. Now it is well known that HIF1A regulates a variety of physiologic pathways, such as hematopoietic stem cell regulation, cell proliferation, survival, apoptosis, angiogenesis, glucose metabolism, and also immune cell activation. [4] [5] [6] The number of HIF1A-regulated genes exceeds 1000
as new cell types and conditions are analyzed by new techniques.
14 Thus, dysregulation of HIF1A signaling could result in a variety of pathological conditions. We note here that the EPO gene is a target of EPAS1 (also known as HIF2A), but not HIF1A, although it was initially considered a HIF1A target. 15, 16 Hypoxia-inducible factor-1α
is ubiquitously expressed and the expression of HIF1A is tightly controlled at transcriptional, translational, and posttranslational levels ( Figure 1 ). 8, 17 Among these, posttranslational modification is the most critical HIF1A regulation. The stability of HIF1A protein is regulated by the oxygen-dependent degradation domain through hydroxylation of proline residues 402 and 564 by prolyl hydroxylase domain proteins (PHDs). 18, 19 These modifications favor interaction with the von Hippel-Lindau tumor suppressor protein (VHL) and subsequent proteasomal degradation. 18, 19 Ubiquitously expressing HIF1A subunit inhibitor HIF1AN (also known as FIH1) could also repress HIF1A transcriptional activity under normoxia by hydroxylating the Asp site 803 of HIF1A protein. [20] [21] [22] [23] These critical enzymes for posttranslational modification of HIF1A require oxygen for their catalytic reaction. Thus, hypoxia could inhibit those posttranslational modifications of HIF1A, stabilize HIF1A protein, and also keep HIF1A transcriptional activity.
As described below in detail, accumulating evidence has revealed multiple cases of hypoxia-independent activation of HIF1A signaling ( Figure 1 ). 8 , and α-ketoglutarate for their catalytic reaction. Thus, as well as oxygen, several oncometabolites can inhibit these enzymes. Mouse double minute 2 homolog (MDM2)/p53, receptor for activated C kinase 1 (RACK1), and glycogen synthase kinase-3β (GSK3B) are involved in the VHL-independent ubiquitination processes for HIF1A protein. Deubiquitination of HIF1A protein could also affect HIF1A protein stability. ARNT, aryl hydrocarbon receptor nuclear translocator; Asn, asparagine; CBP, CREB-binding protein; Pro, proline; ROS, reactive oxygen species; UCHL1, ubiquitin C-terminal hydrolase-L1; USP20, ubiquitin specific peptidase 20
Somatic mutations in the VHL gene or inactivation of VHL gene expression are also common in a majority of patients with sporadic clear cell renal carcinoma. 25 Given that VHL is a critical E3 ubiquitin ligase, which recognizes PHD-mediated hydroxylation of proline residues, for oxygen-dependent HIF1A protein degradation, 18, 19 
| RACK1andHSP90
Heat shock protein 90 (HSP90) binds to the basic helix-loop-helix (bHLH)-PER-ARNT-SIM (PAS) domain of HIF1A protein and regulates HIF1A activation. 29 Receptor for activated C kinase 1 (RACK1) competes with HSP90 for binding to the bHLH-PAS domain. 30 It has been reported that disruption of the interaction between HSP90
and HIF1A protein by HSP90 inhibitor could allow RACK1 to bind HIF1A protein, resulting in the recruitment of the E3 ubiquitin ligase complex and degradation of HIF protein. 30 In this process, phosphorylation of RACK1 and its dimerization is required for Elongin-C, a 
| USP20andUCHL1
Deubiquitination of HIF1A protein also results in stabilization of HIF1A protein. Ubiquitin specific peptidase 20 (USP20, also known as VDU2) has been reported to specifically deubiquitinate and stabilize HIF1A protein. 32 Ubiquitin C-terminal hydrolase-L1 (UCHL1) is also a well-studied deubiquitinase and its association with multiple cancers has been reported. 33 Recently, UCHL1 was identified as a novel regulator of HIF1A signaling activation. 34 UCHL1 could abrogate VHL-mediated HIF1A ubiquitination. Notably, the expression level of UCHL1 in breast and lung cancers was positively correlated with that of HIF1A and poor prognosis. 34 
| TR ANSCRIP TIONALAND TR ANS L ATIONALREG UL ATIONOFHIF1 A
Although HIF1A is mainly regulated at the protein level, HIF1A
is also regulated at the transcriptional and translational levels.
Activation of the PI3K/AKT/mTOR signaling cascade is well known to upregulate both HIF1A mRNA transcription and HIF1A protein translation. 14, 35 This means that multiple growth factors, activation of oncogenes, and mutations in tumor suppressor genes (such as PTEN) could activate HIF1A signaling through the PI3K/AKT/ mTOR pathway. 35 Glycogen synthase kinase-3β (GSK3B) is known to phosphorylate HIF1A protein, leading to degradation of HIF1A protein in a VHL-independent manner. 17 Notably, PI3K/AKT signal could inactivate GSK3B, resulting in HIF1A protein stabilization. 17 Interestingly, GSK3B deficiency in hematopoietic stem cells has been reported to cause MDS. 36 Considering our recent report showing HIF1A is a critical mediator of MDS pathogenesis, 7 GSK3B deficiency could cause MDS phenotypes through HIF1A signaling activation.
Several growth factors and oncogenic events could also activate RAS signaling through the RAS/RAF/MEK/ERK cascade, leading to acceleration of HIF1A protein synthesis. 8 Notably, ERK activation also enhances HIF1A transcriptional activity through phosphorylation of CBP/p300, a critical co-factor for HIF1A transcriptional activity. 8 
| RE AC TIVEOX YGENSPECIES-MEDIATED HIF1ASIGNALINGAC TIVATION
Reactive oxygen species (ROS) are involved in HIF1A signaling activation. In the late 1990s, it was shown that mitochondria generates abundant ROS under hypoxic conditions and this could activate HIF1A signaling. 37 This finding was further confirmed by several studies, 38, 39 in which PHD inactivation was proposed as a mechanism of the ROS-mediated HIF1A signaling activation. However, the mechanisms of ROS-mediated stabilization of HIF1A in hypoxia remain to be elucidated. 40, 41 In contrast, it is evident that ROS could stabilize HIF1A protein under normoxia. 39 IDHs cause an aberrant accumulation of D(R)-2HG. 60, 61 On the other hand, it has recently been shown that L(S)-2HG can be produced in response to hypoxia. 62 Importantly, both of the 2HG enantiomers could competitively inhibit α-KG-dependent dioxygenases due to the structural analogy between 2HG and α-KG. 63 However, it has also been reported that D(R)-2HG, but not L(S)-2HG, rather stimulates PHD activity resulting in degradation of HIF1A protein in astrocytes. 64 It might depend on cell types, conditions, or other factors. Thus, there is still controversy regarding the effect of 2HG enantiomers, especially D(R)-2HG, on PHDs and HIF1A regulation.
| Lactate
Hypoxia-inducible factor-1α is known to be a critical regulator of glycolysis as multiple key enzymes of the glycolysis pathway are direct targets of HIF1A. Lactate dehydrogenase (LDH) is a tetramer which is constituted by 2 subunits, LDHA and LDHB. 65 Both LDHA and LDHB are induced by HIF1A, and involved in the conversion between pyruvate and lactate, a glycolytic end product. Notably, LDHA primarily converts pyruvate to lactate, whereas LDHB converts lactate to pyruvate. 65 It has been reported that lactate is involved in cell migration, invasion, immune escape, and radioresistance of cancer cells. 66 Recently, it was reported that circulating lactate is converted to pyruvate by LDHB and could be the primary carbon source for the mitochondrial TCA cycle. 67, 68 This indicates that the glycolytic end product can be effectively used as a fuel for cancers, resulting in the growth advantage of cancer cells. 67 Importantly, lactate could induce HIF1A activation thorough inhibition of PHD-mediated proline hydroxylation. 69, 70 Pyruvate has also been reported to induce pseudohypoxic conditions. and epithelial-mesenchymal transition. 41 Cellular glucose metabolism, 76 mitochondrial function, 77 and production of ROS 38 are also affected by hypoxic conditions. Acute and chronic hypoxia affect the pathobiology of cancers differently. 78, 79 Furthermore, hypoxia affects the epigenetic networks in tumor cells. 80, 81 The local hypermethylation of the CpG-rich promotors of the tumor suppressor genes is well known in a wide variety of neoplasms. 82, 83 The tet methylcytosine dioxygenases (TETs) are critical enzymes involved in DNA demethylation through oxidizing 5-methylcytosine on DNA. 35 The identification of hypoxic cells in tumors by Thomlinson and Gray and the discovery of HIF1A by Semenza has provided a certain clue as to the mystery of activated glucose metabolism in cancer cells. 2, 3 Hypoxic conditions could induce HIF1A, a master regulator of glucose metabolism, and activate the expression of key enzymes for glycolysis. It appears to be reasonable to explain the Warburg effect as a part of the adaptation process of cancer cells to hypoxic conditions. However, glucose metabolism is also activated in many cancer cells under normoxic conditions. Now it has become clear that HIF1A signaling can also be activated through hypoxiaindependent multiple mechanisms ( Figure 1) . 8 This indicates that glucose metabolism could be activated even in normoxia. Thus, pseudohypoxia-mediated HIF1A signaling activation might well explain the Warburg effect.
| PS EUDOHYP OXIAANDTHEWARBURG EFFEC T

| CON CLUDINGREMARK S
Accumulating evidence has revealed a variety of hypoxiaindependent mechanisms for HIF1A signaling activation. 7, 8 As a result of HIF1A signaling activation, the glycolysis pathway is activated, leading to accumulation of pyruvate and lactate. As described above, accumulation of lactate could stabilize HIF1A and also benefit cancer cells by being involved in cell migration, invasion, immune escape, and radioresistance of cancer cells. 41 Both lactate F I G U R E 2 Hypoxia-inducible factor-1α (HIF1A) signaling activation and epigenome hypermethylation in hypoxia and pseudohypoxia. Hypoxia and pseudohypoxia (especially oncometabolites, such as succinate, fumarate, and 2-hydroxyglutarate could inhibit the prolyl hydroxylase domain (PHD)-von Hippel-Lindau tumor suppressor protein axis and HIF1A subunit inhibitor FIH, leading to activation of HIF1A signaling. Hypoxia and pseudohypoxia also inhibit the activity of histone demethylases, tet methylcytosine dioxygenases (TETs), and fat-mass and obesity-associated protein (FTO)-AlkB homolog 5 (ALKBH5) as they are α-ketoglutarate-dependent enzymes. me, methyl group and pyruvate could be substrates for the mitochondrial TCA cycle in cancer cells. 67, 68, 88 In addition to genes related to the glycolysis pathway, HIF1A regulates many critical genes involved in tumor progression, metastasis, and resistance to therapies. Thus, activation of HIF signaling, regardless of the oxygen situation, is advantageous to cancer cells for their survival and development.
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